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Abstract
Occupational dermatitis (OCD) is a skin inflammatory disease caused by allergens and
irritant agents in the workplace. The disease is related to hypersensitivity reaction,
which is correlated with an immunological mechanism (allergic contact dermatitis)
and a nonimmunological mechanism (irritant contact dermatitis). Patients with atopic
history (rhinitis allergy, asthma, and atopic dermatitis) have a higher risk of contracting
OCD. Atopic individuals suffer from barrier skin damage that increases the risk of
allergen and irritant penetration. Inflammatory reaction involves T-helper 1 (Th1),
which produces cytokine tumor necrosis factor alpha (TNF-α) and interferon-γ (INF-γ),
while T-helper 2 (Th2) produces interleukin (IL-4, IL-6, IL-8, IL-10). Eicosapentaenoic
acid (EPA) is an omega-3 substance from polyunsaturated free fatty acids (PUFAs)
that has been shown to have an anti-inflammatory effect and the ability to decrease
macrophage accumulation. In the inflammatory process, EPA inhibits IL-6, IL-8, and
TNF-α, which are mediated by the free fatty acid-binding proteins (FABPs). The aim
of this study was to determine the bioactivity compound of EPA for anti-inflammatory
agents and its target, based on in silico screening. The bioinformatic tools based
on reverse docking used in this study were the PubChem compound database, the
protein target prediction database, PharmMapper, SwissTargetPrediction, molecular
docking software PyRx 0.8, ligand docking, and binding site analysis using PyMOL
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software. Docking and binding site analysis showed that EPA was able to interact with
FABPs, with the binding affinity of EPA with FABP 4 higher (–4.2 kcal/mol) than that of
hydrocortisone with FABP 4 (–7.4 kcal/mol). EPA has the same binding site and relative
bonding power as the FABPs; thus, it has potential as an alternative anti-inflammatory
medicine in OCD.
Keywords: occupational dermatitis, eicosapentaenoic acid (EPA), free fatty acid bind-
ing proteins (FABPs), reverse docking
1. Introduction
The National Institute of Occupational Safety and Health (NIOSH) has included der-
matologic disorders among the top 10 work-related diseases and injuries in the United
States. The most common injuries are caused by lacerations, punctures, abrasions, and
burns. Occupational contact dermatitis (OCD) is a skin inflammatory disease caused
by allergens and irritant agents at the workplace. The disease is related to hyper-
sensitivity reaction, which is correlated with an immunological mechanism (allergic
contact dermatitis) and a nonimmunological mechanism (irritant contact dermatitis)
[1]. Contact dermatitis accounts for 90 percent of occupational skin diseases. Among
host-related factors, atopic dermatitis has been the most investigated risk factor in the
development of occupationally induced skin diseases, particularly adult atopic hand
dermatitis. Individual atopic dermatitis has a reduced threshold for developing irritant
contact dermatitis from soap, detergents, solvents, and chemical irritants [1, 2].
Patients with atopic history (rhinitis allergy, asthma, and atopic dermatitis) have
a higher risk of contracting OCD. Atopic individuals suffer from barrier skin damage
that increases the risk of allergen and irritant penetration. The inflammatory reac-
tion involves T-helper 1 (Th1), which produces tumor necrosis factor alpha (TNF-α)
and interferon-γ (INF-γ), while T-helper 2 (Th2) produces interleukin (IL-4, IL-6, IL-8,
IL-10). The worldwide prevalence of AD has increased in the past three decades. It
often begins during early childhood, and adult patients frequently suffer from chronic
diseases.The etiology of atopic dermatitis is unknown, but most individuals who are
affected are diagnosed with allergic manifestations (e.g., asthma, food allergies, sea-
sonal allergies), and there is no definitive treatment for AD [1–3].
Polyunsaturated free fatty acids (PUFAs) such as eicosapentaenoic acid (EPA) have a
major impact on human health, for example, causingmotor and cognitive development
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disorders, mental health and psychiatric disorders, and cardiovascular disorders as well
as immunologic and inflammatory responses [4]. EPA cannot be produced by human
bodies; it is primarily found in dietary fish oils and can also be derived from plant
products such as margarine [4, 5]. EPA has been shown to have anti-inflammatory
effects, and its biological effects are mediated by the production of pre-resolving
mediators, which have been proposed to modulate and likely resolve inflammatory
responses[5, 6]. This study aims to discover the natural bioactivity compounds of
eicosapentaenoic acid (EPA) derived from fish oils and margarine for the treatment
of occupational contact dermatitis, based on in silico screening.
2. Methods
2.1. Ligand preparation
The 3D chemical structure and simplified molecular-input line-entry system (SMILES)
of EPAwere obtained from the PubChem compounds database (https://pubchem.ncbi.
nlm.nih.gov/) with ID number: CID 446284.
2.2. Target selection
The target protein for EPA was obtained by entering SMILES into multiple servers,
for example, SwissTargetPrediction (http://www.swisstargetprediction.ch/) and Phar-
mMapper (http://59.78.96.61/pharmmapper/submit_file.php). The servers provided
lists of predicted target proteins for EPA; these were compared, and target proteins
with the most potential as ligands (EPA) were selected.
2.3. Molecular docking
Molecular docking for EPA, the target proteins, and the compound control was per-
formed using the PyRx 0.8 software.
2.4. Molecular visualization and intermolecular interaction
Interaction between EPA, the target proteins, and the control compounds was visu-
alized and analyzed using PyMOL and LigPlus as well as the BIOVIA Discovery Studio
2016 Client.
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3. Results
The results of the target selection using PharmMapper ( job ID: 17091218418) and Swis-
sTargetPrediction (SMILES: CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O) were obtained. The
potentially interactive target protein with EPA was fatty acid-binding protein 4 (FABP
4). FABP 4 belongs to a family of cytosol proteins with a small molecular weight (15
kDa) that is bound in high affinity to unsaturated long-chain fatty acids. FABP 4 plays
a role in the active regulation of lipid trafficking and inflammatory activities and is
clearly expressed in almost all tissues with high rates of fatty acid uptake and lipid
metabolism [7, 8]. Fatty acids shift to long-chain fatty acids that are transported by
FABPs to various tissues, where they are metabolized, stored, or utilized [8]. Fatty
acids such as EPA can be metabolized into a large, diverse family of bioactive lipid
mediators called eicosanoids, which may function as anti-inflammatory mediators [9–
11].
Figure 1: Results of molecular docking 3D structure between target proteins (fatty acid-binding protein
4), candidate ligand (eicosapentaenoic acid), and control ligand (hydrocortisone), which indicate that the
ligands are capable of interacting with target proteins on the same binding site. Description: green (FABP
4), blue (EPA), red (hydrocortisone).
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Figure 2: Visualization of the interaction between eicosapentaenoic acid (EPA) and fatty acid-binding
protein 4 (FABP 4) using Discovery Studio Client BIOVIA, 2016. (a) EPA (blue) is bound to target proteins
(FABP 4); (b) the distance of the type of interaction or bonding between EPA and FABP 4; (c) the types
of interactions between the amino acids of EPA and FABP 4.
 
  (a) (b)    (c) 
Figure 3: Visualization of the interaction between hydrocortisone and fatty acid-binding protein 4 (FABP
4) using Discovery Studio Client BIOVIA, 2016. (a) Hydrocortisone (red) is bound to target proteins (FABP
4); (b) the distance of the type of interaction or bonding between hydrocortisone and FABP 4; (c) the
types of interaction between the amino acids of hydrocortisone and FABP 4.
4. Discussion
Reverse docking is a computing-based method that can be used to search for patterns
of interaction involving molecular docking (drug/ligand) on a potential binding site
on a set of clinically relevant macromolecule targets. The results of reverse docking
between fatty acid-binding protein 4 (PDB ID: 3P6H) resolutions of 1:41 Å, with a
candidate ligand (EPA) and a control ligand (hydrocortisone), using the software PyRx
0.8, showed the binding affinity of EPA with FABP 4 to be higher (–4.2 kcal/mol) than
that of hydrocortisone with FABP 4 (–7.4 kcal/mol). Then the docking results visualized
using the software PyMOL indicated that the candidate ligand (EPA) and the control
ligand (hydrocortisone) were able to interact with the FABP 4 on the same binding site
(Figure 1).
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The bond and location of the ligand binding site on a target protein were visualized
with the BIOVIA Discovery Studio 2016 Client. The results of the visualization showed
that EPA interacts with FABP 4 through the alkyl bond from amino acid Leu 90 (5.18
Å) of FABP 4 (Figure 2). Hydrocortisone interacts with FABP 4 through an alkyl bond
of amino acid Lys 17 (3.90 Å) and a bond unfavorable bump of amino acid Gly 18 (1.95
Å) (Figure 3).
5. Conclusion
This study proves that EPA has potential as an anti-inflammatory agent in OCD by inter-
acting with fatty acid-binding protein 4 (FABP 4), which activates anti-inflammatory
effects. EPA and hydrocortisone are able to interact with the FABP 4 on the same bind-
ing site. When the binding affinity of EPA has a higher bond than that of hydrocortisone,
it has the potential to be an alternative anti-inflammatory medicine in OCD cases.
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